Big Gains For Pain Therapy Stocks Today: KG, PTIE, WPI, ENDP

So Pfizer is increasing their portfolio with King Pharmaceuticals, a maker of veterinary meds and pain therapies.  In addition to this news, another company came into the spotlight for pain management therapies.  This company is Pain Therapeutics (PTIE).  Pain Therapeutics is in clinical trials now in collaboration with King Pharmaceuticals so look for Pfizer to kick in some clinical trial expertise with Pain Therapeutics (PTIE).  Additional companies involved in pain therapies is Endo Pharmaceuticals.  I highly suggest buying Endo as a buy right now.  Since June 2010 Endo's stock has risen form 20.22 to its current trading at 34.99.  I suggest a limit order to buy at some discount.  Another Pain therapies stock is Watson Pharmaceuticals, a generic drug maker. 

My opinion on this is that Pain Therapeutics could be slightly overvalued on the hyped news, and although it may seem attractive to buy right now, I suggest waiting for the pullback as it will be years before these clinical trials are actually approved by the FDA.  Also, I am a little cautious placing a buy on Pfizer right now as they will be losing patents on Lipitor next year and other brand name drugs will become available as generics.  I might actually place Pfizer's stock right now on hold or sell, as earnings could be lower than expected.  Just because everyone is doing it does not make it a buy in my opinion. I actually do not necessarily see King Pharmaceuticals as such a hot buy with only 4.85% profit margin and 18M in profits on 380M in revenue.  But given that layoff will presume who knows. 

Stick to your guns and remain a cautious investor and good things will come.  I apply Warren Buffett's principles to the BioPharma Stock World and like purchasing stocks at a discount.  You should be searching for the next Pfizer and not chasing after something that is overly hyped.  Just my opinion.

Stocks mentioned in this article

Pfizer--(PFE)
King Pharmaceuticals --(KG)
Endo Pharmaceuticals --(ENDP)
Pain Therapeutics --(PTIE)  Up 18.56% today on the news
Watson Pharmaceuticals--(WPI)

Thursday's Top Performing Biotech and Pharmaceutical Stocks

Dismal day again on Wall Street as Unemployment Data showed 500,000 new jobless claims and increased fears of a double dip recession are mounting. Also, a fear in tax hikes with the end of Bush Tax cuts ending in 135 days. The economy is very nervous and jittery. Luckily BioPharma plays can go up regardless of all of this negative news. Unfortunately, not as much as they used to because of nervous investors who sell, sell, sell before FDA decisions. I understand though. I wouldn't want to lose a lot of money because of a negative recommendation either. Sometimes you have to go with your gut on some things and let it ride.

Big news with Intel buying McAfee for a premium as McAfee's stock rose 57%. But the BioPharma market painted a different picture with most stocks down for the day between 1-2% overall. Tomorrow is a big day for Jazz Pharma with FDA recommendation panel for their Fibramyalgia medication. I expect approval and a strong day for Jazz. If not then it will go down heavily. But I just don't see that happening as the medication is already approved for Necrolepsy. There is a huge safety concern for the medication as outlined in yesterday's Wall St. Journal article FDA Raises Concerns About Fibromyalgia Drug. This being said I am letting it ride tomorrow and if it goes up it goes up, if it goes down it goes down. We will see.

Investment plays I currently like are BioElectronics BIEL, Amarin AMRN, and Exact Sciences EXAS. Jiangbo Pharmaceuticals JGBO has been gaining strength lately with a Strong Buy rating, Endo Pharmaceuticals ENDO, and KV Pharmaceuticals KVA.


Thursday's Top Performing Pharmaceuticals

Top Performing Biotech and Pharmaceuticals for Wednesday August 18th

Image via CrunchBase Today was a good day for recommendations and Friday gets even better with Jazz Pharmaceuticals presenting August 20th to the FDA for their Fibramyalgia medication JZP-6 sodium oxybate. Jazz had huge gains this morning as the FDA handed out their review of the clinical trial. Jazz shot up around the 11.90 mark and has been so oversold that right now it's pushing 10.49 in afterhours trading. It has been All Over The Map Today. Speaking of all over the map, BSD Medical exploded today with their medical device approval from the FDA. Just exploded all over the map. What a day.

Jazz was disappointing in the fact that everyone sold. Everyone is scared to death to leave it in the market for the FDA decision. Shoot the dice and let it roll sometimes. But we know where most people stand on this one. I'm taking my profits and waiting for tomorrow where I kick myself for selling. This one's a no-brainer in my department for Approval tomorrow.

Top Performing Biotech Stocks for Wednesday August 18th